Onco Wiki / Red flag

PV / ET patient with positive HBV serology, latent TB, or chronic infection — primarily r...

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Red Flag Origin

Trigger Logic

{
  "any_of": [
    {
      "finding": "hbsag",
      "value": "positive"
    },
    {
      "finding": "anti_hbc_total",
      "value": "positive"
    },
    {
      "finding": "hcv_rna",
      "value": "positive"
    },
    {
      "finding": "latent_tb",
      "value": true
    },
    {
      "finding": "active_uncontrolled_infection",
      "value": true
    }
  ],
  "type": "composite"
}

Notes

Direction "investigate" — workup-prerequisite annotation. HU itself is not strongly immunosuppressive, so infection-screening is mostly a forward-looking concern for ruxolitinib (RESPONSE 2L) or interferon-α (preferred for pregnancy / younger patients). HBV / TB screening before JAKi initiation per NCCN. STUB — requires clinical co-lead signoff.

Used By

Algorithms

• ALGO-ET-1L - ALGO-ET-1L
• ALGO-PV-1L - ALGO-PV-1L
• ALGO-PV-2L - ALGO-PV-2L

Indications

• IND-ET-2L-ANAGRELIDE - IND-ET-2L-ANAGRELIDE
• IND-PV-2L-RUXOLITINIB - IND-PV-2L-RUXOLITINIB